Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression

Dan Han;Jiangxue Li;Huamin Wang;Xiaoping Su;Jin Hou;Yan Gu;Cheng Qian;Yun Lin;Xiang Liu;Mingyan Huang;楠 李;Weiping Zhou;Yizhi Yu;雪涛 曹

Zhejiang University;Second Military Medical University;Chinese Academy of Medical Sciences;Hospital of Hepatobiliary Surgery

发表时间:2017-10

期 刊:Hepatology

语 言:English

U R L: http://www.scopus.com/inward/record.url?scp=85025147139&partnerID=8YFLogxK

摘要

Noncoding RNAs play important roles in cancer biology, providing potential targets for cancer intervention. As a new class of endogenous noncoding RNAs, circular RNAs (circRNAs) have been recently identified in cell development and function, and certain types of pathological responses, generally acting as a microRNA (miRNA) sponge to regulate gene expression. Identifying the deregulated circRNAs and their roles in cancer has attracted much attention. However, the expression profile and function of circRNAs in human hepatocellular carcinoma (HCC) remain to be investigated. Here, we analyzed the expression profile of human circRNAs in HCC tissues and identified circMTO1 (mitochondrial translation optimization 1 homologue; hsa_circRNA_0007874/hsa_circRNA_104135) as one circRNA significantly down-regulated in HCC tissues. HCC patients with low circMTO1 expression had shortened survival. By using a biotin-labeled circMTO1 probe to perform RNA in vivo precipitation in HCC cells, we identified miR-9 as the circMTO1-associated miRNA. Furthermore, silencing of circMTO1 in HCC could down-regulate p21, the target of oncogenic miR-9, resulting in the promotion of HCC cell proliferation and invasion. In addition, the tumor-promoting effect of circMTO1 silencing was blocked by miR9 inhibitor. Intratumoral administration of cholesterol-conjugated circMTO1 small interfering RNA promoted tumor growth in HCC-bearing mice in vivo. Conclusion: circMTO1 suppresses HCC progression by acting as the sponge of oncogenic miR-9 to promote p21 expression, suggesting that circMTO1 is a potential target in HCC treatment. The decrease of circMTO1 in HCC tissues may serve as a prognosis predictor for poor survival of patients. (Hepatology 2017;66:1151-1164).

相关科学

医学
肝脏病学

被引量

期刊度量

Scopus度量

年份 CiteScore SJR SNIP
1996
1997
1998
1999 2.067 2.07
2000 2.834 2.215
2001 2.934 2.165
2002 3.26 2.462
2003 3.524 2.614
2004 3.721 2.746
2005 3.57 2.675
2006 4.142 2.778
2007 4.138 2.659
2008 4.767 2.637
2009 4.4 2.729
2010 4.801 2.746
2011 17.6 5.012 2.829
2012 18.5 5.2 2.861
2013 18.1 5.29 2.691
2014 17.3 5.155 2.606
2015 18 4.879 2.623
2016 19.9 5.229 2.756
2017 20.6 5.541 2.746
2018 20.7 5.096 2.856
2019 20.6 5.377 3.171
2020 21.7

相似文献推荐